Ultragenyx Pharmaceutical (RARE) Other Accumulated Expenses (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Other Accumulated Expenses for 14 consecutive years, with $17.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 407.77% year-over-year to $17.0 million; the TTM figure through Mar 2026 stood at $17.0 million (up 407.77% YoY), while the FY2025 annual figure was $19.0 million, up 375.0% from the prior year.
• Other Accumulated Expenses slipped to $17.0 million in Q1 2026 per RARE's latest filing, from $19.0 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $59.9 million in Q3 2022 and bottomed at $1.2 million in Q3 2025.
• Historically, Other Accumulated Expenses has averaged $30.7 million across 5 years, with a median of $31.2 million in 2023.
• Annual changes were most pronounced in 2025 — Other Accumulated Expenses slumped 93.33% — and 2026, when it soared 407.77%.
• Ultragenyx Pharmaceutical's Other Accumulated Expenses stood at $52.2 million in 2022, then slumped by 40.22% to $31.2 million in 2023, then sank by 87.18% to $4.0 million in 2024, then surged by 375.0% to $19.0 million in 2025, then slipped by 10.53% to $17.0 million in 2026.
• Business Quant data shows RARE's Other Accumulated Expenses at $17.0 million in Q1 2026, $19.0 million in Q4 2025, and $1.2 million in Q3 2025.